Cantor Fitzgerald Estimates Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Kura Oncology in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings of ($2.94) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

A number of other research firms also recently issued reports on KURA. HC Wainwright boosted their price target on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. Scotiabank dropped their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Wedbush restated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Finally, Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.38.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $8.21 on Wednesday. The firm has a market cap of $638.41 million, a PE ratio of -3.48 and a beta of 0.81. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a 50 day simple moving average of $9.88 and a 200-day simple moving average of $16.09.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter in the previous year, the company posted ($0.50) earnings per share.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently bought and sold shares of KURA. Harbor Capital Advisors Inc. lifted its holdings in Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after purchasing an additional 2,076 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Kura Oncology by 0.8% in the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares during the period. Armistice Capital LLC lifted its stake in shares of Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after buying an additional 302,000 shares during the last quarter. Alethea Capital Management LLC boosted its holdings in shares of Kura Oncology by 2.4% during the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock worth $5,475,000 after buying an additional 6,300 shares during the period. Finally, AQR Capital Management LLC grew its stake in Kura Oncology by 251.5% in the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after buying an additional 58,422 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.